Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?
Expert Opin Biol Ther
.
2020 Aug;20(8):831-836.
doi: 10.1080/14712598.2020.1767062.
Epub 2020 May 26.
Authors
Leticia Moreno-Fierros
1
,
Ileana García-Silva
2
,
Sergio Rosales-Mendoza
2
Affiliations
1
Faculty of Higher Studies Iztacala, National Autonomous University of Mexico , Tlalnepantla, Estado De México, México.
2
Faculty of Chemical Sciences and Center for Health Sciences, Autonomous University of San Luis Potosí , San Luis Potosi, México.
PMID:
32380868
DOI:
10.1080/14712598.2020.1767062
No abstract available
Keywords:
COVID-19; Oral vaccine; intranasal vaccine; mucosal adjuvant; sIgA.
Publication types
Editorial